Showing results (221-230 of 258) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|August 26, 2025
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 studyElisa Lucchini, Nicola Vianelli, Ugo Consoli, et al.
Cancer|April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcomeFrancesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
European Journal of Haematology|September 16, 2025
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter StudyMaria Carmen Martorelli, Novella Pugliese, Maria Di Perna, et al.
Cancers|July 29, 2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET StudyFrancesca Palandri, Elena Rossi, Giuseppe Auteri, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Pageof 26